RFX6 haploinsufficiency predisposes to diabetes through impaired beta cell function
Diabetologia · 2024
DOI: 10.1007/s00125-024-06163-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologia, 2024. Verfasst von Hazem Ibrahim und 18 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. hazem.ibrahim@helsinki.fi. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Haploinsufficiency, Regulatory Factor X Transcription Factors. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Excellence of Diabetes Research in Sweden, Svenska Diabetesstiftelsen, Biomedicum Helsinki-säätiö.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims/hypothesis Regulatory factor X 6 (RFX6) is crucial for pancreatic endocrine development and differentiation. The RFX6 variant p.His293LeufsTer7 is significantly enriched in the Finnish population, with almost 1:250 individuals as a carrier. Importantly, the FinnGen study indicates a high predisposition for heterozygous carriers to develop type 2 and gestational diabetes. However, the precise mechanism of this predisposition remains unknown.
Methods
To understand the role of this variant in beta cell development and function, we used CRISPR technology to generate allelic series of pluripotent stem cells. We created two isogenic stem cell models: a human embryonic stem cell model; and a patient-derived stem cell model. Both were differentiated into pancreatic islet lineages (stem-cell-derived islets, SC-islets), followed by implantation in immunocompromised NOD-SCID-Gamma mice.
Results
Stem cell models of the homozygous variant RFX6 −/− predictably failed to generate insulin-secreting pancreatic beta cells, mirroring the phenotype observed in Mitchell–Riley syndrome. Notably, at the pancreatic endocrine stage, there was an upregulation of precursor markers NEUROG3 and SOX9 , accompanied by increased apoptosis. Intriguingly, heterozygous RFX6 +/− SC-islets exhibited RFX6 haploinsufficiency (54.2% reduction in protein expression), associated with reduced beta cell maturation markers, altered calcium signalling and impaired insulin secretion (62% and 54% reduction in basal and high glucose conditions, respectively). However, RFX6 haploinsufficiency did not have an impact on beta cell number or insulin content. The reduced insulin secretion persisted after in vivo implantation in mice, aligning with the increased risk of variant carriers to develop diabetes. Conclusions/interpretation Our allelic series isogenic SC-islet models represent a powerful tool to elucidate specific aetiologies of diabetes in humans, enabling the sensitive detection of aberrations in both beta cell development and function. We highlight the critical role of RFX6 in augmenting and maintaining the pancreatic progenitor pool, with an endocrine roadblock and increased cell death upon its loss. We demonstrate that RFX6 haploinsufficiency does not affect beta cell number or insulin content but does impair function, predisposing heterozygous carriers of loss-of-function variants to diabetes. Data availability Ultra-deep bulk RNA-seq data for pancreatic differentiation stages 3, 5 and 7 of H1 RFX6 genotypes are deposited in the Gene Expression Omnibus database with accession code GSE234289. Original western blot images are deposited at Mendeley ( https://data.mendeley.com/datasets/g75drr3mgw/2 ). Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. hazem.ibrahim@helsinki.fi.
- Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
- Institute for Molecular Medicine Finland, FIMM, HiLIFE, Helsinki, Finland.
- Research Program of Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland.
- Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Finland.
Förderung
- Excellence of Diabetes Research in Sweden
- Svenska Diabetesstiftelsen
- Biomedicum Helsinki-säätiö
- Barndiabetesfonden
- Suomen Kulttuurirahasto
- Research Council of Finland
- Magnus Ehrnroothin Säätiö
- Svenska Forskningsrådet Formas
Zitieren
APA
Ibrahim, H., Balboa, D., Saarimäki-Vire, J., Montaser, H., Dyachok, O., Lund, P. E., Omar-Hmeadi, M., Kvist, J., Dwivedi, O. P., Lithovius, V., Barsby, T., Chandra, V., Eurola, S., Ustinov, J., Tuomi, T., Miettinen, P. J., Barg, S., Tengholm, A., & Otonkoski, T. (2024). RFX6 haploinsufficiency predisposes to diabetes through impaired beta cell function. Diabetologia. https://doi.org/10.1007/s00125-024-06163-y
Vancouver
Ibrahim H, Balboa D, Saarimäki-Vire J, Montaser H, Dyachok O, Lund PE, et al. RFX6 haploinsufficiency predisposes to diabetes through impaired beta cell function. Diabetologia. 2024. doi:10.1007/s00125-024-06163-y
BibTeX
@article{Ibrahim2024,
author = {Ibrahim, Hazem and Balboa, Diego and Saarimäki-Vire, Jonna and Montaser, Hossam and Dyachok, Oleg and Lund, Per-Eric and Omar-Hmeadi, Muhmmad and Kvist, Jouni and Dwivedi, Om P and Lithovius, Väinö and Barsby, Tom and Chandra, Vikash and Eurola, Solja and Ustinov, Jarkko and Tuomi, Tiinamaija and Miettinen, Päivi J and Barg, Sebastian and Tengholm, Anders and Otonkoski, Timo},
title = {RFX6 haploinsufficiency predisposes to diabetes through impaired beta cell function},
journal = {Diabetologia},
year = {2024},
doi = {10.1007/s00125-024-06163-y}
}
EUVIMED